WENTWORTH KORY JAMES 4

What Happened
Kory J. Wentworth, Chief Financial Officer of Entrada Therapeutics (TRDA), sold 7,988 shares in an open-market sale. The reported weighted-average price was $12.25 per share, for aggregate proceeds of approximately $97,892. The sale was reported on Form 4 covering transactions on March 4, 2026.

Key Details

• Transaction date: March 4, 2026; Form 4 filed March 6, 2026 (appears timely).
• Shares sold: 7,988; weighted-average price: $12.25; total proceeds: ~$97,892.
• Price range: sales executed at prices between $11.80 and $12.57 (multiple trades); the filer can provide per-price breakdown on request (see footnote).
• Footnote: Transactions were made under a Rule 10b5-1 trading plan adopted March 6, 2025.
• Shares owned after the transaction: not disclosed in the information provided.

Context
A sale by an executive is often routine (e.g., planned selling under a 10b5-1 plan) and does not by itself indicate the company’s prospects. The 10b5-1 plan note confirms these trades were pre-planned; the price range note indicates multiple executions. Retail investors should view this as a scheduled insider sale rather than an ad hoc sign of sentiment.